Liminal BioSciences Inc. (LMNL)

$0.5293

+0.03 (+5.86%)
Rating:
Recommendation:
-
Symbol LMNL
Price $0.5293
Beta 1.540
Volume Avg. 0.04M
Market Cap 16.431M
Shares () -
52 Week Range 0.365-4.18
1y Target Est -
DCF Unlevered LMNL DCF ->
DCF Levered LMNL LDCF ->
ROE 86.54% Strong Buy
ROA 29.21% Buy
Operating Margin -
Debt / Equity 164.79% Buy
P/E 0.93 Buy
P/B 0.63 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LMNL news


Mr. Kenneth Galbraith
Healthcare
Biotechnology
NASDAQ Global Market

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.